Ditching Big Drugmakers for Biotech Brings Leukemia Boon

Fifty-five, pensionless and assuming he’d have to work until he died, Roger Ulrich had a decision to make. After two decades in the pharmaceutical industry, his position at Merck & Co. had been phased out.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.